USANA Health Sciences Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences or view top-rated stocks.

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for USANA Health Sciences.

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, April, 27th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by $0.12. USANA Health Sciences had a net margin of 10.57% and a trailing twelve-month return on equity of 32.91%.
View USANA Health Sciences' earnings history.

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, USNA shares have increased by 39.3% and is now trading at $97.35.
View which stocks have been most impacted by COVID-19.

USANA Health Sciences declared that its Board of Directors has authorized a stock buyback program on Tuesday, February 9th 2021, which permits the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 8.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's leadership believes its shares are undervalued.

USANA Health Sciences issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 6.150-6.500 for the period, compared to the Thomson Reuters consensus estimate of $6.280. The company issued revenue guidance of $1.24 billion-$1.28 billion, compared to the consensus revenue estimate of $1.24 billion.

2 brokerages have issued 1 year price objectives for USANA Health Sciences' stock. Their forecasts range from $126.00 to $126.00. On average, they expect USANA Health Sciences' stock price to reach $126.00 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for USANA Health Sciences or view top-rated stocks among Wall Street analysts.

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to USANA Health Sciences include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Medifast (MED), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of USNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.36%), Assenagon Asset Management S.A. (0.33%), Robeco Institutional Asset Management B.V. (0.22%), Rhumbline Advisers (0.17%), Swiss National Bank (0.14%) and Exchange Traded Concepts LLC (0.08%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, New York State Teachers Retirement System, Texas Permanent School Fund, Strs Ohio, Comerica Bank, and The Manufacturers Life Insurance Company . Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences or view top insider-selling stocks.

USNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Exchange Traded Concepts LLC, Denali Advisors LLC, Pacer Advisors Inc., 6 Meridian, Janney Montgomery Scott LLC, and Everence Capital Management Inc..
View insider buying and selling activity for USANA Health Sciences or or view top insider-buying stocks.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of USNA stock can currently be purchased for approximately $97.35.

USANA Health Sciences has a market capitalization of $2.01 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis.

USANA Health Sciences employs 1,943 workers across the globe.

The official website for USANA Health Sciences is www.usana.com.

USANA Health Sciences is headquartered at 3838 West Parkway Blvd, Salt Lake City UT, 84120.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]